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ABSTRACT 
The architectural chromatin binding proteins High Mobility Group A1 (HMGA1) are proteins 
expressed at high levels in malignant cancers and induce neoplastic transformation. The protein is 
increased as the last step of the Wnt/-catenin/TCF-4 pathway and mediates drug resistance, 
therefore correlating with a poor patient prognosis. HMGA1-mediated chemoresistance results from 
a self-protective process called cellular senescence. Analogs of the antioxidant, curcumin, when used 
in combination with traditional chemotherapeutic agents, are useful treatment options for drug 
resistant tumors. This study had two specific aims. The first being to investigate how colon cancer 
cells HCT116 respond to treatment with EF24. The second aim was to evaluate how hmga1 
expression changed as a result of treatment with EF24. Our preliminary findings showed that cell 
viability decreased after 24-hour treatment with low-dose EF24, as indicated by an MTS assay, with 
notable discrepancies between cells that underwent a pulsed treatment regimen versus those that 
underwent continuous treatment. Furthermore, we demonstrated that cells exhibited fragmented 
DNA when treated with low-dose EF24, which is characteristic of apoptotic cells. At higher, pulsed 
doses, senescence activity increased, indicating the induction of a senescence pathway. Lastly, gene 
expression studies indicated that hmga1 was significantly down regulated in cells treated with 
continuous, low-dose EF24. Further investigation of this pathway could lead to decreased toxicity 
and increased viability of combination cancer therapies.  
 
INTRODUCTION 
The High Mobility Group A1 
(HMGA1) family of proteins are non-histone 
binding architectural proteins. They are aptly 
named based on their high mobility in 
polyacrylamide gel (Reeves, 2001). The sub-
family consists of two isoforms, HMGA1a and 
HMGA1b, which are the result of alternately 
spliced mRNA transcripts derived from the 
common hmga1 gene. The HMGA1 proteins are 
characterized by a prominent binding domain 
that preferentially binds to AT-rich regions on 
the minor groove of DNA (Reeves, 2001).  This 
allows the protein to alter shape of B-form 
DNA and control the transcription of a variety 
of genes and the activity of a variety of proteins 
(Thanos et al., 1992). Depending on the context, 
HMGA1 can promote or repress a variety of 
molecular pathways. As a result, the HMGA 
family participates in a number of cellular 
processes including cellular proliferation, 
neoplastic transformation, aging and metastasis 
(Reeves, 2001).  
 Hmga1 was identified as a gene that is 
induced by growth factors, and is required by 
cells to pass through the G1/S cell cycle 
checkpoint (Fedele et al., 2001). More 
importantly, HMGA1 functions as an oncogene 
when overexpressed in those same cells (Resar, 
2010). Therefore, it follows that hmga1 is up-
regulated in a number of malignant cancers 
including, but not limited to: ovarian, breast, 
lung, thyroid, and colon cancers (Scala et al., 
2000). When tissue samples from normal, 
unaffected mice were compared to their 
metastatic counterparts, the HMGA1 levels 
were almost undetectable; suggesting that 
HMGA1 plays an important role in the 
transformation of cells from normal to 
malignant (Xu et al., 2004). Furthermore, when 
compared to localized tumors, hmga1 was vastly 
up-regulated in the metastatic counterparts. 
Similarly, malignant tissues in which hmga1 is 
overexpressed exhibit increased resistance to 
common chemotherapeutic drugs. When hmga1 
expression is inhibited, sensitivity to the same 
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drugs increased significantly (D’Angelo et al., 
2014). Taken together, these factors suggest that 
there is a correlation between high levels of 
hmga1 expression and poor patient prognosis. 
 When a malignant cell undergoes 
therapeutic treatment, it triggers a number of 
responses; the two most prominent responses 
are apoptosis and a protective cellular process 
known as senescence (Childs et al., 2014). 
Previous research shows that HMGA1 disrupts 
normal cell cycle regulation by preventing 
malignant cells from undergoing apoptosis 
while simultaneously propelling it through 
mitosis (Fedele et al., 2001). Contrastingly, 
HMGA1 also promotes cellular senescence 
(Narita et al, 2006). Senescence is characterized 
by arrest of the cell cycle, expression of SA--
galactosidase and induction of tumor 
suppressors p16 and p21. Senescent cells can 
then induce a change in phenotype in 
surrounding cells through emission of an 
intercellular signal (Narita et al, 2006).  
 Curcumin, the active ingredient of the 
turmeric plant, possesses novel antioxidant, 
anti-inflammatory and anti-proliferative 
properties. Studies show that malignant tissues 
treated with curcumin exhibited elevated levels 
of HMGA1 and subsequently induced apoptosis 
and senescence (Kuo et al., 1996; Jin et al., 2016 
and Mosieniak et al., 2016). However, a clinical 
study showed that curcumin presents with low 
bio-availability (Ramasamy et al., 2015 and 
Cheng et al., 2001). EF24 is a chemically 
synthesized analog of curcumin, however its 
exact anti-proliferative mechanism remains 
relatively unknown. 
  Taken together, we sought to 
investigate the relationship between hmga1 
expression and treatment with EF24, with two 
specific questions in mind. How does hmga1 
expression change upon treatment with EF24? 
How do HCT116 cells respond to treatment 
with EF24? It was shown that upon treatment 
with low-dose, continuous EF24, hmga1 
expression was down-regulated. Furthermore, 
cell viability decreased significantly upon 
treatment with both continuous and pulsed 
EF24. Lastly, at low concentrations of EF24, 
there was evidence of apoptosis, whereas at 
higher concentrations there was increased 
evidence of senescence. Further investigation 
into this nexus could lead to the discovery of a 
viable, targeted combination cancer therapy. 
 
METHODS 
Cell Culture 
The HCT116 human colon cancer cell 
line was obtained from the American Type 
Culture Collection (ATCC). Cells were 
maintained in McCoy’s 5A media supplemented 
with 10% fetal bovine serum and 1% Penicillin-
Streptomycin-Amphotericin B. Cells were 
maintained in a humidified incubator at 37°C 
and 5% CO2. 
RNA Extraction and RT-PCR 
HCT116 cells were treated with varying 
concentrations of EF24 (0.0, 0.25, 0.5 M) for 
24h. After 24h, total RNA was isolated using 
the QuickRNA Mini Prep kit following the 
manufacturer’s instructions. GAPDH was used 
as a positive control. The forward and reverse 
primers for both HMGA1 and GAPDH are 
shown below: 
Primer Sequence 
HMGA- Forward 5’- GAT GGG ACT 
GAG AAG CGA-3’ 
HMGA1-Reverse 5’-CTT CTC CAG TTT 
CTT GGG TC-3’ 
GAPDH- Forward  5’-TGC ACC ACC 
AAC TGC TTA GC-3’ 
GAPDH-Reverse 5’-GGC ATG GAC 
TGT GGT CAT GAG-
3’ 
 
The assembled reactions were run using the 
following thermal cycler program: 
Temperature 
(°C) 
Time # of cycles 
50 15 min 1 
95 15 min 1 
95 20 s 
25 55 30 s 
72 1 min 
72 5 min 1 
 
Cell Viability MTS Assay 
Approximately 6000 cells were plated 
per well in a 96-well plate, and were incubated 
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for 24h. Cells were then treated with increasing 
concentrations of EF24 for 24h. For continuous 
treatment, the treated cells were assayed for cell 
viability following 24h EF24 treatment using 
CellTiter Aqueous One Solution Cell 
Proliferation Assay. For pulsed treatment, the 
treated media was removed, replaced with drug-
free media and cells were incubated for an 
additional 48h. Following the 48h recovery, cells 
were assayed for cell viability. Cell viability was 
quantified by measuring absorbance at 490nm. 
Apoptosis Assay 
HCT116 cells were plated in a 6-well 
plate and treated with increasing EF24 
concentrations (0.0, 0.05, 0.125 M) for 24h. 
Treated media was then removed, and cells were 
cultured in drug-free media for an additional 
48h. Genomic DNA was then isolated and the 
fragments were resolved on a stained agarose 
gel. 
SA--galactosidase Activity Senescence Assay 
Approximately 10,000 cells were plated 
per well in a 6-well plate and incubated for 24h. 
Cells were then treated with increasing 
concentrations of EF24 (0.0, 0.05, 0.125 M) 
and incubated for 24h. Treated media was 
removed and replaced with drug free media and 
incubated for an additional 48h. Cells were lysed 
and galactosidase activity was assayed using 
the 96-well Cellular Senescence Assay Kit (Cell 
Biolabs Inc.) Enzyme activity was quantified by 
measuring absorbance at 360nm. 
 
RESULTS 
EF24 Treatment Down-Regulates hmga1 Expression 
HMGA1 has a well-established link to 
the phenotype of colon cancer cells. Therefore, 
we initially analyzed the effect EF24 treatment 
had on hmga1 expression. Treatment with EF24 
had a significant effect on the expression of 
hmga1 in HCT116 cells. As the concentration of 
EF24 increased, the expression of the gene was 
three to four-fold down regulated (Figure 1). 
 
 
 
 
 
 
 
Figure 1. HMGA1 mRNA Levels in HCT116 Cells 
Treated with Low-Dose EF24 are Down-Regulated 
Quantitative real time RT-PCR shows HMGA1 mRNA 
levels in treated HCT116 cells are significantly down-
regulated when compared to untreated cells (p<0.05) 
 
Continuous EF24 Treatment Decreases Cell Survival 
The HMGA1 is a key player in 
oncogenic transformation because it allows cells 
to ignore normal growth pathways and cell cycle 
regulations, resulting in abnormal proliferation. 
Upon observing that treatment with EF24 
resulted in a down-regulation of hmga1, we 
decided to test for cell viability after a 
continuous 24h treatment. Figure 2 indicates 
that there was a significant decrease in cell 
viability from 100% to approximately 65% at 
low doses of EF24. With a gradual decrease in 
cell viability as the concentration of EF24 
increases. 
Figure 2. HCT116 Cells Treated with Continuous 
Low-Dose EF24 Experienced Decreased Cell 
Survival Cell proliferation assays showed treated 
HCT116 cells were significantly less viable when 
compared to untreated cells (p<0.05) 
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Pulsed EF24 Treatment Decreases Cell Survival and 
Induces Apoptosis 
Chemotherapeutic treatment follows a 
treatment-recovery model. Patients undergo 
treatment for a period, which is then directly 
followed by a period of recovery. We sought to 
mimic that model by allowing the cells to 
recover post-treatment. Figure 3A indicates 
that there was a significant decrease in cell 
viability from 100% to 15% at low doses of 
EF24. Cell viability was noticeably low across 
the board, indicating that cells were unable to 
recover after the treated media was removed 
regardless of EF24 concentration. 
The prominent decrease in cell viability 
prompted the need to observe the mechanism 
by which the cells were dying, particularly at low 
doses. DNA isolated from untreated cells and 
from cells treated with 0.05 M EF24 presented 
with fragmented DNA. Contrastingly, cells 
treated with 0.125M presented with solely 
whole DNA (Figure 3B). 
 
 
Figure 3. HCT116 Cells Treated with Pulsed Low-
Dose EF24 Experienced Apoptosis (A) Cell viability 
assays show that there was a significant decrease in cell 
viability between treated cells and untreated cells 
(p<0.05) (B) Isolated DNA from treated cells was 
resolved to show the presence of fragments.  
 
Increased Concentrations of EF24 Induce Senescence 
It has been shown that curcumin, the 
naturally occurring counterpart of EF24, has the 
capacity to force cells into a protective process 
known as senescence. The absence of 
fragmented DNA upon treatment with higher 
concentrations of EF24 leads us to believe that 
the cells may have been forced out of the cell 
cycle into cellular senescence. Figure 4 is 
indicative of an increase in senescence 
associated -galactosidase activity from 
untreated to treated. However, the difference in 
activity was not found to be statistically 
significant.   
Figure 4. HCT116 Cells   Treated with Pulsed Low-
Dose EF24 Exhibited Increased SA--
galactosidase Activity SA--galactosidase assays 
showed that enzymatic activity increased as 
concentration of EF24 treatment increased. However, 
results were not statistically significant. 
 
DISCUSSION 
HMGA1 is overexpressed in a variety 
of different malignant tumors (Scala et al., 2000). 
Not only does it facilitate the neoplastic 
transformation of normal cells, it also facilitates 
drug resistance and abandonment of the cell 
cycle while simultaneously inhibiting 
programmed cell death (Xu et al., 2004; 
D’Angelo et al., 2014; and Fedele et al., 2001).  
Recent studies have shown that HMGA1 also 
plays a role in the promotion of cellular 
senescence (Narita et al, 2006). The present 
study investigated the relationship between 
HMGA1 expression and EF24 in colon cancer 
cells. The data indicates that treatment with 
EF24 significantly decreases cell viability at low-
doses and down-regulates hmga1 expression. 
Furthermore, upon pulsed treatment with low 
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doses, both apoptotic and senescent activity are 
exhibited. 
As previously mentioned, expression of 
hmga1 results in the inhibition of p53 mediated 
apoptosis (Fedele et al., 2001). Therefore, it 
follows that upon treatment with therapeutic 
agent, EF24, hmga1 expression should decrease. 
This hypothesis was confirmed by PCR analysis.  
Upon down-regulation of hmga1, the normal cell 
cycle should resume resulting in a decrease in 
overall cell viability. This trend is observed in 
the cells treated with continuous EF24.  
Therefore, EF24 is effective in reducing the 
viability of colon cancer cells as a first wave 
attack.  However, this model of treatment does 
not accurately represent most modern 
chemotherapy treatments. 
Chemotherapy follows a treatment-
recovery model. Patients are treated for a short 
period of time and allowed to recover. This 
method is employed as a means of protecting 
non-malignant cells from repetitive attack by 
harmful chemotherapeutic drugs. Therefore, an 
optimal chemotherapeutic compound should 
not continue to kill cells during the recovery 
period. Doing so would put vital stem cells at 
risk of being compromised. Keeping this in 
mind, the colon cancer cells were treated with 
EF24 using a pulsed treatment model. The 
results indicated that cell viability decreased 
significantly despite the 48-hour recovery 
period. This prompted us to investigate exactly 
what was happening to the cells to compromise 
their viability. The apoptosis assay showed 
evidence of fragmented DNA in both the 
untreated cells and cells that were treated with 
the lowest concentration of EF24. However, at 
higher concentrations, the band that was 
indicative of fragmented DNA disappears. 
Taken together with the data from the 
senescence assay leads us to postulate that at 
higher, pulsed concentrations, cells forego the 
apoptotic pathway in favor of the protective 
cellular senescence pathway. When cells are 
continuously treated with drugs, some will die 
and some will enter senescence (Childs et al., 
2014). However, the 24-hour treatment time 
might not be long enough to allow the 
senescent cells to signal neighboring cells to 
enter senescence. Contrastingly, when cells are 
treated using a pulsed regimen, the cells that 
have entered senescence can continue to signal 
neighboring cells even after the treated media is 
removed resulting in the drastic decrease in cell 
viability observed in Figure 3A.  
Continuing to study the role of 
HMGA1 in the cellular response of colon 
cancer following treatment with EF24 may 
contribute to the discovery and development of 
less toxic combination cancer therapies. 
 
FUTURE WORK 
To confirm the hypothesis that 
treatment using a pulsed regimen promotes 
cellular senescence, both apoptosis and 
senescence assays need to be conducted using 
cells that have been treated with a continuous 
treatment model. Furthermore, hmga1 
expression studies need to be done using cells 
treated with a pulsed treatment model. 
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